“The company expects preliminary revenue for the third quarter ended September 30, 2025, to be approximately $17 million. In connection with the company’s credit agreement with OrbiMed, the company has secured a waiver for the third quarter 2025 trailing 12-month net revenue covenant, and is in discussions with OrbiMed to redefine future covenants. While the outcome of those discussions is yet to be determined, the parties remain focused on maintaining a constructive agreement. The company is assessing annual guidance and will provide an update on the company’s third quarter earnings call scheduled for November 6,” Avita Medical (RCEL) stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- Avita Medical CEO Corbett leaving, Chairman Vance appointed Interim CEO
- Avita Medical downgraded to Hold from Buy at Lake Street
- Avita Medical Appoints Cary Vance as Interim CEO
- Avita Medical to be eligible for NTAP reimbursement from CMS for RECELL
- Avita Medical says data shows hospital stay reduction with RCELL System